


## Labtech

Companies in the Labtech business are active in the market areas diagnostics, biomedical research and laboratory equipment.




MSEK	3 months ending			6 months ending			12 months ending	
	30 Jun 22	30 Jun 21	change	30 Jun 22	30 Jun 21	change	30 Jun 22	31 Dec 21
Net sales	786	1,169	-33%	2,066	2,394	-14%	4,045	4,373
EBITA	117	280	-58%	413	556	-26%	834	977
EBITA-margin, %	14.9%	23.9%		20.0%	23.2%		20.6%	22.3%

Labtech's net sales decreased by 33 percent in the quarter to SEK 786m (1,169), where of organic sales, excluding COVID-19 related sales, amounted to 4 percent and acquired growth was 5 percent. Net sales related to COVID-19 decreased by 85 percent and accounted for SEK 87m (569). Exchange rate changes had positive impact of 2 percent on net sales. EBITA decreased by 58 percent to SEK 117m (280), corresponding to an EBITA-margin of 14.9 percent (23.9).




Labtech's net sales decreased by 14 percent in the interim period to SEK 2,066m (2,394), where of organic sales, excluding COVID-19 related sales, amounted to 6 percent and acquired growth was 4 percent. Net sales related to COVID-19 decreased by 51 percent and accounted for SEK 546m (1,108). Exchange rate changes had positive impact of 3 percent on net sales. EBITA decreased by 26 percent to SEK 413m (556), corresponding to an EBITA-margin of 20.0 percent (23.2).



For the Labtech business, the changes in the second quarter have been significant due to the decrease in sales of COVID-19 products, compared to last year, and a return to a more normal customer offering. PCR testing has declined in all countries and is now focused on patients requiring hospital care, and hospital staff. Future sales of COVID-19 tests in our diagnostics companies depend entirely on how the pandemic evolves, new mutations and different testing requirements in society. We expect that customers will primarily request combination tests – “4-plex solutions” – for the autumn and winter flu season. Our diagnostics businesses report solid underlying growth in our traditional areas, including blood gas analysis, pathology and microbiology, with increased sample volumes in existing instruments.

Sales to research customers have also been affected by a decrease in sequencing of COVID-19 mutations in the quarter. On the other hand, demand has increased for more traditional laboratory reagents for gene sequencing, cell therapy and cancer immunology. Sales have also increased for instruments and special microscopes, but at the same time delivery times have become extended due to component shortages. In the first half -year, we have seen strong growth in sales of our own advanced instruments in the US, Europe and China.




## Medtech

Companies in the Medtech business provides medical device products within the medtech market and assistive equipment within home healthcare.




MSEK	3 months ending			6 months ending			12 months ending	
	30 Jun 22	30 Jun 21	change	30 Jun 22	30 Jun 21	change	30 Jun 22	31 Dec 21
Net sales	1,296	1,108	17%	2,597	1,620	60%	4,602	3,625
EBITA	129	57	127%	273	107	156%	476	310
EBITA-margin, %	10.0%	5.1%		10.5%	6.6%		10.4%	8.6%

For the quarter, Medtech's net sales increased by 17 percent to SEK 1,296m (1,108), of which organic growth, excluding COVID-19 related sales, amounted to 5 percent and acquired growth was 22 percent. Net sales related to COVID-19 accounted for SEK 0m (135). Exchange rate fluctuations had a positive impact of 4 percent on net sales. EBITA increased by 127 percent to SEK 129m (57) and EBITA margin amounted to 10.0 percent (5.1). Development cost regarding digital solutions for self-monitoring has had a negative impact on the result of SEK 11m.




For the interim period, Medtech's net sales increased by 60 percent to SEK 2,597m (1,620), of which organic growth, excluding COVID-19 related sales, amounted to 1 percent and acquired growth was 67 percent. Net sales related to COVID-19 accounted for SEK 0m (215). Exchange rate fluctuations had a positive impact of 6 percent on net sales. EBITA increased by 156 percent to SEK 273m (107) and EBITA margin amounted to 10.5 percent (6.6). Development cost regarding digital solutions for self-monitoring has had a negative impact on the result of SEK 14m.



The growth in the second quarter in the Medtech business area is driven both by the acquisitions made in recent years as well as by an increase in the number of planned operations. Operations are increasing in all countries, while at the same time the shortage of healthcare workers following the pandemic has restricted capacity. The recurrent spread of new mutations has also led to operations being cancelled at the end of the quarter. In summary, this means that recovery is taking longer and healthcare queues continue to grow.

Sales have increased above all in the orthopaedics, respiratory medicine and endoscopy segments, while ophthalmology and neurology have shown slightly weaker growth. Our largest acquisition from 2021, Healthcare 21, has performed strongly in the quarter while integrating the O'Flynn acquisition in Ireland at the same time. At AddVision, sales in Poland and for self-manufactured products have performed positively, but the recovery in other markets is slower. MBA, which we acquired in the first quarter, delivered as expected.

All home care companies have experienced positive growth in the quarter. Market activity has been buoyant, with an increased number of customer visits and product trials. Interest in our digital solutions for both alarms and self-monitoring is high, and two additional installations were made in Swedish municipalities during the quarter. As planned, we continue to invest in the further development of the acquired digital platform.



## Net sales by business area

Quarterly data, SEKm	2022				2021	
	Q2	Q1	Q4	Q3	Q2	Q1
Labtech	786	1,280	1,089	890	1,169	1,225
Medtech	1,296	1,301	1,043	962	1,108	512
Group items	-3	-2	-1	-2	-1	-1
<b>AddLife Group</b>	<b>2,079</b>	<b>2,579</b>	<b>2,131</b>	<b>1,850</b>	<b>2,276</b>	<b>1,736</b>

## EBITA by business area

Quarterly data, SEKm	2022				2021	
	Q2	Q1	Q4	Q3	Q2	Q1
Labtech	117	296	227	194	280	276
Medtech	129	144	108	95	57	50
Parent Company and Group items	-6	-5	-6	-3	-5	0
<b>EBITA</b>	<b>240</b>	<b>435</b>	<b>329</b>	<b>286</b>	<b>332</b>	<b>326</b>
Depreciation intangible assets	-102	-97	-84	-79	-79	-35
<b>Operating profit</b>	<b>138</b>	<b>338</b>	<b>245</b>	<b>207</b>	<b>253</b>	<b>291</b>
Finance income and expenses	-44	-49	-22	-27	-16	-4
<b>Profit after financial items</b>	<b>94</b>	<b>289</b>	<b>223</b>	<b>180</b>	<b>237</b>	<b>287</b>

## Net sales by business area

SEKm	3 months ending			6 months ending			12 months ending	
	30 Jun 22	%	30 Jun 21	30 Jun 22	%	30 Jun 21	30 Jun 22	31 Dec 21
Labtech	786	-33	1,169	2,066	-14	2,394	4,045	4,373
Medtech	1,296	17	1,108	2,597	60	1,620	4,602	3,625
Group items	-3		-1	-5		-2	-8	-5
<b>AddLife Group</b>	<b>2,079</b>	<b>-9</b>	<b>2,276</b>	<b>4,658</b>	<b>16</b>	<b>4,012</b>	<b>8,639</b>	<b>7,993</b>

## EBITA and EBITA-margin by business area and operating profit for the group

SEKm	3 months ending				6 months ending				12 months ending			
	30 Jun 22	%	30 Jun 21	%	30 Jun 22	%	30 Jun 21	%	30 Jun 22	%	31 Dec 21	%
Labtech	117	14.9	280	23.9	413	20.0	556	23.2	834	20.6	977	22.3
Medtech	129	10.0	57	5.1	273	10.5	107	6.6	476	10.4	310	8.6
Parent Company and Group items	-6		-5		-11		-5		-20		-14	
<b>EBITA</b>	<b>240</b>	<b>11.6</b>	<b>332</b>	<b>14.6</b>	<b>675</b>	<b>14.5</b>	<b>658</b>	<b>16.4</b>	<b>1,290</b>	<b>14.9</b>	<b>1,273</b>	<b>15.9</b>
Depreciation intangible assets	-102		-79		-199		-114		-362		-277	
<b>Operating profit</b>	<b>138</b>	<b>6.7</b>	<b>253</b>	<b>11.1</b>	<b>476</b>	<b>10.2</b>	<b>544</b>	<b>13.6</b>	<b>928</b>	<b>10.7</b>	<b>996</b>	<b>12.5</b>
Finance income and expenses	-44		-16		-93		-20		-142		-69	
<b>Profit after financial items</b>	<b>94</b>		<b>237</b>		<b>383</b>		<b>524</b>		<b>786</b>		<b>927</b>	

## Net sales by revenue type

SEKm	3 months ending		6 months ending		12 months ending	
	30 Jun 22	30 Jun 21	30 Jun 22	30 Jun 21	30 Jun 22	31 Dec 21
<i>Products</i>						
Labtech	503	986	1,548	1,991	3,075	3,518
Medtech	1,022	947	2,107	1,421	3,734	3,048
Group items	-3	-1	-5	-2	-8	-5
<b>The Group</b>	<b>1,522</b>	<b>1,932</b>	<b>3,650</b>	<b>3,410</b>	<b>6,801</b>	<b>6,561</b>
<i>Instruments</i>						
Labtech	211	140	367	312	728	673
Medtech	172	84	285	122	509	346
<b>The Group</b>	<b>383</b>	<b>224</b>	<b>652</b>	<b>434</b>	<b>1,237</b>	<b>1,019</b>
<i>Service</i>						
Labtech	72	44	151	91	242	182
Medtech	102	76	205	77	359	231
<b>The Group</b>	<b>174</b>	<b>120</b>	<b>356</b>	<b>168</b>	<b>601</b>	<b>413</b>
<b>Total</b>	<b>2,079</b>	<b>2,276</b>	<b>4,658</b>	<b>4,012</b>	<b>8,639</b>	<b>7,993</b>